Hosted by Castor Ventures Partner Cainon Coates
Please join us for a discussion with Daniel Dornbusch, CEO of Excision. This Castor Ventures portfolio company is using CRISPR gene-editing technology to develop novel therapeutics to cure viral infections including HIV/AIDS, Covid-19, Herpes Virus, Hepatitis B, JC Virus, and others. As featured in Time Magazine, Excision is the first and only company to functionally cure HIV in animals and plans to start human clinical trials early next year.
Currently, people with HIV require lifelong medication of antiretroviral therapy (ART) drugs that suppress viral replication, but do not eliminate the virus that persists in the body. When ART is stopped, HIV returns within weeks. Without fully curing HIV, patients are prone to HIV-related side effects (e.g., kidney issues, liver problems, HIV-associated dementia). Excision’s innovative approach targets viral DNA – the source of the infection – and uses CRISPR, a powerful gene editing technology, to remove the virus and generate a cure.
Join our webinar on Wednesday, September 23rd at 3pm ET to learn more about Excision and their cure for HIV/AIDS.